ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för momelotinib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

45 träffar

Bibliografisk träff 2018-01-08

Pharmacokinetics and Disposition of Momelotinib Revealed a Disproportionate Human Metabolite-Resolution for Clinical Development.

Zheng J, Xin Y, Zhang J, Subramanian R, Murray BP, Whitney JA, Warr MR, Ling J, Moorehead L, Kwan E, Hemenway J, Smith BJ, Silverman JA.

Drug Metab Dispos · research support, non-u.s. gov't; journal article · DOI 10.1124/dmd.117.078899

Bibliografisk träff 2017-12-28

Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment.

Xin Y, Kawashima J, Weng W, Kwan E, Tarnowski T, Silverman JA.

J Clin Pharmacol · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1002/jcph.1050

Bibliografisk träff 2017-12-20

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.

Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, Passamonti F, Winton EF, Dong H, Kawashima J, Maltzman JD, Kiladjian JJ, Verstovsek S.

Lancet Haematol · clinical trial, phase iii; randomized controlled trial; journal article · DOI 10.1016/s2352-3026(17)30237-5

Bibliografisk träff 2017-11-16

Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis.

Pardanani A, Gotlib J, Roberts AW, Wadleigh M, Sirhan S, Kawashima J, Maltzman JA, Shao L, Gupta V, Tefferi A.

Leukemia · letter; clinical trial, phase ii; research support, non-u.s. gov't; clinical trial, phase i · DOI 10.1038/leu.2017.330

Bibliografisk träff 2017-10-11

The Relative Bioavailability, Food Effect, and Drug Interaction With Omeprazole of Momelotinib Tablet Formulation in Healthy Subjects.

Xin Y, Shao L, Maltzman J, Stefanidis D, Hemenway J, Tarnowski T, Deng W, Silverman JA.

Clin Pharmacol Drug Dev · research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1002/cpdd.397

Bibliografisk träff 2017-09-27

JAK1/2 Inhibitors AZD1480 and CYT387 Inhibit Canine B-Cell Lymphoma Growth by Increasing Apoptosis and Disrupting Cell Proliferation.

Lu Z, Hong CC, Jark PC, Assumpção ALFV, Bollig N, Kong G, Pan X.

J Vet Intern Med · research-article; journal article · DOI 10.1111/jvim.14837

Bibliografisk träff 2017-09-20

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.

Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib J.

J Clin Oncol · clinical trial, phase iii; comparative study; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1200/jco.2017.73.4418

Bibliografisk träff 2017-05-30

A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia.

Verstovsek S, Courby S, Griesshammer M, Mesa RA, Brachmann CB, Kawashima J, Maltzman JD, Shao L, Xin Y, Huang D, Bajel A.

Leuk Res · clinical trial, phase ii; research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1016/j.leukres.2017.05.002

Bibliografisk träff 2016-10-27

Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.

Winton EF, Kota V.

Future Oncol · review; journal article · DOI 10.2217/fon-2016-0417

Bibliografisk träff 2016-09-15

A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.

Gupta V, Mesa RA, Deininger MW, Rivera CE, Sirhan S, Brachmann CB, Collins H, Kawashima J, Xin Y, Verstovsek S.

Haematologica · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.3324/haematol.2016.148924

Bibliografisk träff 2014-12-15

Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis.

Abdelrahman RA, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, Pardanani A, Tefferi A.

Br J Haematol · clinical trial, phase iii; clinical trial, phase ii; clinical trial, phase i; journal article · DOI 10.1111/bjh.13262

Bibliografisk träff 2014-11-11

Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis.

Pardanani A, Abdelrahman RA, Finke C, Lasho TT, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, Hanson CA, Ketterling RP, Tefferi A.

Leukemia · letter; clinical trial, phase ii; research support, non-u.s. gov't; clinical trial, phase i · DOI 10.1038/leu.2014.306

Bibliografisk träff 2013-03-05

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A, Hogan WJ, Litzow MR, Leontovich A, Kowalski M, Tefferi A.

Leukemia · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/leu.2013.71

Bibliografisk träff 2010-11-16

JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.

Pardanani A, Vannucchi AM, Passamonti F, Cervantes F, Barbui T, Tefferi A.

Leukemia · research support, non-u.s. gov't; review; journal article · DOI 10.1038/leu.2010.269

Bibliografisk träff 2009-08-23

Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs).

Burns CJ, Bourke DG, Andrau L, Bu X, Charman SA, Donohue AC, Fantino E, Farrugia M, Feutrill JT, Joffe M, Kling MR, Kurek M, Nero TL, Nguyen T, Palmer JT, Phillips I, Shackleford DM, Sikanyika H, Styles M, Su S, Treutlein H, Zeng J, Wilks AF.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2009.08.071